Research programme: inflammation therapy - Millennium Pharmaceuticals

Drug Profile

Research programme: inflammation therapy - Millennium Pharmaceuticals

Alternative Names: MLN 6095

Latest Information Update: 07 Apr 2009

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium
  • Class Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 07 Apr 2009 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 04 Jun 2008 Preclinical development is ongoing
  • 14 May 2008 Takeda acquires Millennium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top